An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum.
Kontos
Andrew P
AP
Kerr
Holly A
HA
Fivenson
David P
DP
Remishofsky
Christopher
C
Jacobsen
Gordon
G
D000279:Administration, Cutaneous; D000328:Adult; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D009824:Ointments; D010146:Pain / Q000139:chemically induced; D010352:Patient Dropouts; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000473:pathology; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus